Obesity business grows at Novo Nordisk despite Wegovy woes
Novo Nordisk’s obesity care arm continues to grow despite the recent announcement that the company won’t be able to meet the full demand for weight loss drug Wegovy before the second half of 2022.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk has had the wind in its sails in 2021, and the pharmaceutical firm’s obesity business sales grew by 50 percent in Danish kroner and 55 percent in current exchange rates (CER), according to the company’s 2021 financial report on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Catalent behind Novo Nordisk's supply issues, says media
For subscribers
Production issues could put a damper on Novo Nordisk's 2022
For subscribers
